PCSK9 Inhibitors Might Also Lower Risk for Venous Thromboembolism

In analyses of data from two previously published studies, VTE risk declined with PCSK9 inhibition, especially among patients with high lipoprotein(a) levels.

Multiple studies have found an association between statin use and lower rates of venous thromboembolism (VTE). To assess the effect of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibition on VTE risk, investigators examined data on rates of deep vein thrombosis and pulmonary embolism from the manufacturer-supported FOURIER trial (investigating the PCSK9 inhibitor evolocumab) and ODYSSEY Outcomes trial (investigating the PCSK9 inhibitor alirocumab).

A post hoc analysis of FOURIER found a 29% reduction in VTE associated with evolocumab use (P=0.05), with benefits accruing over time (no effect in year 1 but a subsequent 46% reduction). In a meta-analysis, the authors combined FOURIER and ODYSSEY Outcomes data and found a significant…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)